<DOC>
	<DOC>NCT02536118</DOC>
	<brief_summary>Medtronic is sponsoring the Micra Registry to further confirm safety and effectiveness of the Micra Transcatheter Pacing System (Micra system) when used as intended, in "real-world" clinical practice, following commercial release. The Micra Registry is conducted within Medtronic's Product Surveillance Registry.</brief_summary>
	<brief_title>Micra Transcatheter Pacing System Post-Approval Registry</brief_title>
	<detailed_description>The Micra Registry is a global, prospective, observational, multi-site registry. All patients enrolled in the Micra Registry will be prospectively followed for a minimum of 9 years post implant or until registry closure. Enrolled patients will have scheduled follow-up visits at least annually or as prompted by reportable adverse events; however, all Micra system follow-up patient visits are to be reported. Therefore, if more frequent scheduled visits occur per a provider's standard care practice, those visits are reported. The total estimated registry duration is 11 years.</detailed_description>
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Patient is intended to receive or be treated with a Micra Transcatheter Pacing System and must be enrolled prior to the TPS implant procedure Patient who is, or is expected to be inaccessible for followup Patient with exclusion criteria required by local law Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>